

Trial Design Overview



Setting the
Global Standard
for Clinical Data

**CLINICAL DATA INTERCHANGE
STANDARDS CONSORTIUM**

**Diane Wold
February 1, 2005**

Overview of Trial Design Model

- Purpose and Scope of the TDM
- Current components
 - Trial Inclusion/Exclusion
 - Trial Elements, Arms, and Visits
- New component: Trial Summary
- Future components under development
 - Planned assessments and interventions
- Worked example: a migraine trial
- Relationship to subject-level data
- Implementation issues

Purpose of the Trial Design Model

- Developed to accompany the subject data in the Study Data Tabulation Model (SDTM).
- Regulators need to understand the trial which generated the trial.
- The Trial Design Model (TDM) is a set of trial-level data that summarizes key aspects of the study.
- Trial Design data will allow reviewers to examine how closely the conduct of the trial followed the plan.

“Good parts version” of the Protocol

- Title
- Objectives
- Admission Criteria
- Schema or flowchart
- Time and events table

TDM representation of the “good parts” of the protocol

Title	Trial Summary in proposed SDTM V1.1
Objectives	Trial Summary in proposed SDTM V1.1
Admission Criteria	Trial Inclusion/Exclusion in SDTM Version 1.0
Schema or flowchart	Trial Elements, Trial Arms, Trial Visits in SDTM Version 1.0
Time and events table	Planned interventions and assessments under development

Trial Inclusion/Exclusion

- Currently contains text of admission criteria
- Converting to “executable” form a possible future development

Trial Elements, Arms, Visits

- “Elements” are basic building blocks; may correspond to “periods” or “cycles”
- Arms are paths a subject may take through the study; correspond roughly to treatment groups
- Visits are “clinical encounters”


Trial Summary

- Very simple dataset with parameters and values
- Parameters include title, objectives
- Some of the key characteristics likely to be in the title are also separate parameters, e.g., randomized, double-blind, bioavailability, cross-over, phase 2, placebo-controlled


Planned Assessments and Interventions

- Under development!
- Concepts
 - Assessments
 - Assessment Groups
 - Interventions
 - “Anchors”
 - Element transitions
 - Visits
 - Other events to which assessment or intervention timings are related

Example Migraine Trial Epoch Level




Trial Arms and Elements



→ randomization

→ Skip to follow-up if headache is not treated in 60 days

Add Visits



Visit 1

Visit 2

Time and Events Table

Original version in protocol

Study procedures	Visit 1	Visit 2
Informed consent	X	
Questionnaire 1	X	
Inclusion/Exclusion criteria	X	
Medical/Headache history	X	
Vital Signs	X	
Demographics	X	
Pregnancy test (females of childbearing potential)	X	
Issue Headache Diary and Provide Instruction	X	
Dispense Investigational Product	X	
Review Headache Diary for completeness		X
Adverse Event query		X
Return Unused Investigational product		

Some **procedures** not assessments

Diary data is not included

Protocol includes more detailed instruction

Study procedures	Visit 1	Visit 2
Informed consent	X	
Questionnaire 1	X	
Inclusion/Exclusion criteria	X	
Medical/Headache history	X	
Vital Signs	X	
Demographics	X	
Pregnancy test (females of childbearing potential)	X	
Issue Headache Diary and Provide Instruction	X	
Dispense Investigational Product	X	
Review Headache Diary for completeness		X
Adverse Event query		X
Return Unused Investigational product		X


Revised Time/Assessments Table

Study procedures	Visit 1a (pre-rand)	Visit 1b (post-rand)	Visit 2
Questionnaire 1	X		
Inclusion/Exclusion criteria	X		
Medical/Headache history	X		
Vital Signs	X		
Demographics	X		
Pregnancy test (females of childbearing potential)	X		
Satisfaction questions		X	
Adverse event query			X

Time and Events Table For Diary


	Pre dose	0.5 hrs	1 hr	2 hr	4 hr	24 hr	Return of pain	Re treat	Rescue med
Onset of headache	X								
Study drug	X							X	
Rescue med									X
Pain recurrence							X		
Pain grade	X	X	X	X	X		X	X	X
Symptoms (group 1)	X								
Symptoms (group 2)	X	X	X	X	X				
Ability to perform normal activities	X	X	X	X	X				
Questionnaire 2						X			
Questionnaire 3						X			
Subject preference questions						X			

Data Collection Visits and Diary



Data Collection

Visits and Timepoints within Diary



A = rescue med
B = return of pain
C = retreatment
Note: A, B, C may occur
Any time between 2 & 24 hours

Time and Events Diagram with Epochs, Visits, Timepoints

A = rescue med
B = return of pain
C = retreatment


Screen

Wait

Treatment

Follow-up

- Incl/Excl
- Questionnaire 1
- Medication Hx
- Medical Hx
- Vital Signs
- Demographics
- Pregnancy Test
- Satisfaction Q
- HA onset
- Rescue med
- Recurrence
- HA pain grade
- Symptoms 1
- Symptoms 2
- Activities
- Questionnaire 2
- Questionnaire 3
- Preference
- Adverse Events
- SAEs



Subject Data

- SDTM domains that correspond with trial-level TDM datasets
 - Subject Elements
 - Subject Visits
 - Inclusion/Exclusion
- Most other SDTM domains are the “actuals” that would match planned interventions or assessments

Implementation Issues: Terminology and Paradigm Shift

- “Element” and “epoch” are new terms. Current terms such as “period,” “phase,” or “cycle” may or may not translate directly to elements.
- Users sometimes confuse Elements with Visits. Subjects are always in an element, never in a gap “between elements,” but will often spend most of their time during a trial between visits.
- Deciding how many elements to use is something of an art. For instance, a change in dose may or may not indicate a transition to a new element.

Implementation Issues (2)

- The model allows for branches within arms (TATRANS) as well as branches that separate arms (BRANCH). Deciding which are which is something of an art.
- Subject Elements and Subject Visits data depend on algorithms for deriving Element and Visit start dates. The algorithms may be complex, and subject to differences of opinion.
- We have not yet defined a computer-readable format for rules.

Implementation Issues (3)

- If data was not collected under this paradigm, is it really useful to express the trial in these terms retrospectively?
- Retrospectively modeling a trial may uncover ambiguity in the trial plan, or transition points for which date/times were not collected.